ROLE OF APRIPITANT IN TREATMENT OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

Introduction: Nausea and vomiting associated with chemotherapy agents are most common and can lead to serious side effects, which can cause marked reduction in quality of life (1 – 3). Severity and incidence of CINV depend on the type of anti-cancer drug emetogenically. Emetogenicity of a drug can be divided into three categories—high, moderate, and low or mild. Aprepitant is a neurokinin 1 (NK-1) which has different action mechanism to control or prevent CINV. (13). Aprepitant can block selectively and binding of substance P at NK2 receptor in central nervous system area causes control of acute and delayed CINV. (8,9) All the enrolled patients received tablet aprepitant 125 Material and Method: mg per oral, dexamethasone 8mg intravenous push or in load normal saline 30 minutes prior to chemotherapy on D1, followed by 80mg per oral on D2 and D3. Total 270 Patients were included in this study. 116 were fe Results: males, 144 were males common age group was 40 to 50 year in females. While 50 to 60 year of age was commonest group among males. Commonest site of malignancy was Carcinoma breast, 2nd commonest was Carcinoma gall bladder and 3rd commonest was carcinoma cervix among females.